FDA Approved Indications for this Orphan Drug:The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.
FDA Marketing Approval issued as of:
Orphan Drug exclusivity ends on:
Company Making and Marketing this drug:
FDA Designation Date:
FDA Drug Designation:
Treatment of chronic lymphocytic leukemia.